After accompanying OncoBeta for several years before coming on board, Shannon D. Brown III joined OncoBeta in March of 2017. Prior to joining OncoBeta Shannon had undergone the Rhenium-SCT treatment in its early development stages himself and being a non-melanoma cancer survivor, he is very enthusiastic about making this therapy available to patients all over the world. Shannon studied emergency medicine, hospital management and nursing in the US military. After leaving the military he has held a variety of leadership and management positions over the past 30 years’ in the pharmaceutical and medical device fields with companies such as Basilea as the commercial director DACH (German speaking countries) and TEVA as Marketing and Sales director.
Nicholas H. Vetter joined OncoBeta in Dec of 2016. In the past he has held management positions in Supply Chain Management and Operations Excellence areas. Nicholas holds an advisory board member position of PatchAI and is a Board Observer – Guest of Vetter Pharma. He uses his expertise to lead all operation functions and coordination’s throughout the entire organization. Nick studied Integrative Physiology at the University of Colorado and holds an MBA from SDA Bocconi school of Management.
Martin Reuter joined OncoBeta in December 2015. Martin holds a degree in Business Economics and has held a variety of entrepreneurial and management positions throughout his career. He is acting Managing Director of UV-Cap GmbH & Co KG. and OncoBeta International GmbH. Prior to joining OncoBeta, Martin held the position of Managing Director at Repligen GmbH, Ravensburg for over 7 years. He is on the OncoBeta Advisory Board and Executive Management of the ICPO foundation. At OncoBeta Martin is responsible for corporate finance, controlling, intellectual property management, information systems and business development.